In cancer, apart from triggering apoptosis, TRAIL binding to TRAIL receptors activates non-cell death signaling, which results in the activation of NF-κB and other pro-tumorigenic pathways [42,43,44,45,46]. This evidence concerns the gene NFKB1 and cancer.